Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions, an investment holding company, provides telehealth solutions in Singapore. The company operates in two segments, Telemedicine and Other Services, and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The company also provides a range of primary healthcare services, including general medical consultations, treatment and management of acute and chronic conditions in adults and children, vaccinations, and health screenings for work permit applications, as well as pre-employment health screening, children's health services, geriatric care services, and minor surgical procedures. In addition, it offers healthcare and wellness-related products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace and forum, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical and health services. The company was founded in 2009 and is headquartered in Singapore.

Mobile-health Network Solutions Class A Ordinary Shares trades as MNDR on NASDAQ. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $5.77M of revenue and -$2.55M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Mobile-health Network Solutions Class A Ordinary Shares can be compared against peers such as Ainos, Inc., Artelo Biosciences, Inc., bioAffinity Technologies, Inc., Carisma Therapeutics, Inc., GT Biopharma, Inc., Lipella Pharmaceuticals Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $620,029, beta of -1.12, and return on equity of -124.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MNDR currently shows total debt of $243,872 and beta of -1.12. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 6-K (2026-05-18 00:00:00), 6-K (2026-05-13 00:00:00), 424B3 (2026-05-06 00:00:00), EFFECT (2026-05-04 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://manadr.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.